EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-SA 4.0

Immunohistochemical and molecular diagnostics tailoring personalised ovarian cancer therapy

Adam Michał Kowalewski, Łukasz Szylberg

Polish Journal of Pathology · 2026

DOI: 10.5114/pjp.2026.162571 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Polish Journal of Pathology, 2026. Verfasst von Adam Michał Kowalewski und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumour Pathology, Oncology Centre, Prof. Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Precision Medicine, Biomarkers, Tumor, Immunohistochemistry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer remains the most lethal gynaecological malignancy, and it exhibits substantial histologic and molecular heterogeneity. Traditional systemic therapies have produced only modest survival gains. Integration of immunohistochemical (IHC) and molecular diagnostics has shifted care toward biomarker-driven personalised treatment. This review presents current IHC approaches for histotype classification and the most important actionable protein markers (FR, HER2, TROP2, MMR proteins, and PD-L1), together with molecular testing for BRCA1/2, homologous recombination deficiency (HRD) status, and circulating tumour DNA (ctDNA) monitoring. These diagnostics now direct poly(ADP-ribose) polymerase inhibitors maintenance in HRD-positive disease and antibody-drug conjugates such as mirvetuximab soravtansine in FR-high platinum-resistant tumours. However, important limitations remain: intratumoral heterogeneity, variable assay performance, lack of standardisation, and unequal access to testing worldwide. We also discuss how best to combine multiple biomarkers and outline future directions, such as AI-assisted digital pathology, composite predictive models, and ctDNA-guided adaptive strategies, to refine patient selection and improve long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPrecision MedicineBiomarkers, TumorImmunohistochemistryMolecular Diagnostic TechniquesHumansFemalePredictive Value of Tests

Stichwörter der Autor:innen

PARP inhibitorsantibody-drug conjugatesfolate receptor homologous recombination deficiencyovarian cancerprecision oncology

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Tumour Pathology, Oncology Centre, Prof. Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland.
  • Faculty of Medicine, Bydgoszcz University of Science and Technology, Bydgoszcz, Poland.
  • Department of Obstetrics, Gynecology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Zitieren

APA

Kowalewski, A. M., & Szylberg, Ł. (2026). Immunohistochemical and molecular diagnostics tailoring personalised ovarian cancer therapy. Polish Journal of Pathology. https://doi.org/10.5114/pjp.2026.162571

Vancouver

Kowalewski AM, Szylberg Ł. Immunohistochemical and molecular diagnostics tailoring personalised ovarian cancer therapy. Polish Journal of Pathology. 2026. doi:10.5114/pjp.2026.162571

BibTeX
@article{Kowalewski2026,
  author = {Kowalewski, Adam Michał and Szylberg, Łukasz},
  title = {Immunohistochemical and molecular diagnostics tailoring personalised ovarian cancer therapy},
  journal = {Polish Journal of Pathology},
  year = {2026},
  doi = {10.5114/pjp.2026.162571}
}
Kostenlos starten →